Life and Health Insurance

MANULIFE-S

Manulife Private Credit Enhanced Fund Proposes Share Repurchase Up to $11.4 Million

Manulife Singapore to Launch Shield™ Multi-Cancer Test with Guardant Health in May 2026

Manulife Reports Q1 Core Profit of 1.8 Billion Canadian Dollars

Manulife Reports First Quarter 2026 Results

MANULIFE-S released FY2026 Q1 earnings on May 13 After-Market (BJT), actual revenue HKD 54.79 B (forecast HKD 41.34 B), actual EPS HKD 3.6568

MANULIFE-S to Release FY2026 Q1 Earnings on May 14 After-Market (BJT), Forecast Revenue HKD 41.34 B

Manulife Reduces Management Fees for MPF Plans Benefiting Over 2 Million Members

Manulife Holding Annual Shareholder and Policyholder Meeting in 2026

Manulife Establishes Long-Term Partnership with Legal & General and Appoints New AI Data Officer

L&G and Manulife Wealth and Asset Management Establish Global Strategic Partnership

Manulife Plans to Expand AI Investment in Hong Kong

Guardant Health Partners with Manulife Financial to Launch Shield Multi-Cancer Blood Test in Asia

Manulife Chooses Akka to Implement Agent AI

Sienna Gestion Increased Holdings in Manulife Financial in Q3

Manulife Vietnam Launches Xanh Phu Quy Investment-Linked Life Insurance Product

Manulife Holdings Announces Q4 Earnings and Final Dividend

Manulife Singapore Issues a $300 Million Indexed Universal Life Insurance Policy

Manulife Sells $300 Million Life Insurance Policy, Sets Guinness Record

Mahindra & Mahindra and Manulife Establish 50:50 Life Insurance Joint Venture in India

CFRA Maintains Manulife Financial's Buy Rating and Raises Target Price to $42

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

Ordinary dividend (cash)

Ex Date: 2026.05.28, Cash dividend 2.7596 HKD

00945

Manulife Singapore will launch the Shield™ multi-cancer detection test in May 2026 through its partnership with Guardant Health, becoming the first in Singapore to offer this blood test for multiple cancers. This initiative supports preventive healthcare, addressing the rising demand for early cancer detection. The Shield™ test has received Breakthrough Device Designation from the FDA and was recognized as Oncology Product Innovation of the Year. Manulife aims to empower customers in managing their health and finances.

Singapore Business Review

Guardant Health

Manulife Financial

Ark Genomic Revolution ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

VanEck Biotech ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

Direxion S&P Biotech Bull 3X

China Merchants CSI Biotechnology Theme ETF

Direxion S&P Biotech Bear 3X

Manulife Singapore to offer multi-cancer blood test starting May

RBC Capital Markets suggests that Manulife Financial's Canada business may rebound sooner and stronger than anticipated, though sustained growth requires better performance from Asia and Global Wealth and Asset Management. The company's Q1 core EPS was CA$1.06, below estimates. RBC has lowered its EPS forecasts for 2026 and 2027 and maintains an outperform rating with a price target of CA$55.

Fidelity

ROYAL BANK OF CANADA

Manulife Financial's Canada Business May Rebound Earlier, Stronger Than Expected, RBC Says

CFRA maintains a Buy opinion on Manulife Financial Corp. with a 12-month target price of CAD57. The company reported Q1 2026 core EPS of CAD1.06, exceeding last year's CAD0.99, while net income rose to CAD1.147B. Asia's performance was strong, with core earnings up 22%. Currently, shares are trading at a discount, yielding 3.3%, indicating they are undervalued.

fidelity

Research Alert: CFRA Keeps Buy Opinion On Shares Of Manulife Financial Corp.

Manulife Financial Corporation announced the election of 13 directors at its Annual Meeting of Shareholders. The nominees received significant support, with votes for each ranging from 95.37% to 99.82%. The final voting results will be available on their website and filed with securities regulators. Manulife is a leading international financial services provider, operating as Manulife in Canada and Asia, and John Hancock in the U.S., serving over 37 million customers globally.

StockTitan

Manulife Announces Election of Directors | MFC Stock News

Manulife Financial (NYSE:MFC) shares gapped down from $39.85 to $37.57, last trading at $37.4550. Despite a raised quarterly dividend to $0.485 and strong first-quarter results with core earnings of $1.8 billion, market sentiment was mixed due to underwhelming core ROE and lower U.S. investment spreads. Analysts maintain a "buy" rating with a consensus price target of $51.50. The stock has a market cap of $62.63 billion and a PE ratio of 16.85. Institutional investors have increased their stakes significantly in recent quarters.

Market Beat

Bank of Nova Scottia

Manulife Financial (NYSE:MFC) Shares Gap Down   - Should You Sell?

Manulife Financial (NYSE:MFC) reported solid Q1 2026 results, highlighting strong growth in insurance segments and an 18% increase in the CSM balance, driven by significant sales in Asia. The company achieved an 11% growth in core EPS, despite challenges in Canada. Strategic initiatives include expanding global reach and enhancing distribution capabilities. Manulife maintains a strong balance sheet with a LICAT ratio of 136% and aims for an 18%+ core ROE by 2027. The earnings call provided insights into the company's performance and future strategies.

benzinga_article

Manulife Financial Q1 2026 Earnings Call Transcript

Manulife Financial shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

MANULIFE-S(00945.HK)